Latest Insider moments: SATO VICKI L, Vir Biotechnology Inc. [VIR] Director sold 17,915 shares

0
1

Vir Biotechnology Inc.’s filing revealed that its Director SATO VICKI L unloaded Company’s shares for reported $0.37 million on Oct 10. In the deal valued at $20.67 per share,17,915 shares were sold. As a result of this transaction, SATO VICKI L now holds 1,416,919 shares worth roughly $ 38.6 million.


China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored


Then, SATO VICKI L sold 17,915 shares, generating $392,335 in total proceeds. Upon selling the shares at $21.90, the Director now owns 1,434,834 shares.

Before that, SVF Endurance (Cayman) Ltd sold 7,800 shares. Vir Biotechnology Inc. shares valued at $215,614 were divested by the 10% Owner at a price of $27.64 per share. As a result of the transaction, SVF Endurance (Cayman) Ltd now holds 22,086,280 shares, worth roughly $601.63 million.

SVB Leerink initiated its Vir Biotechnology Inc. [VIR] rating to an Outperform in a research note published on Monday, September 14, 2022; the price target was $40. PT values the company’s stock at a premium of 31.9 to its Monday closing price. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who began to cover the stock in early September with a ‘”an Underweight”‘ rating. Robert W. Baird also remained covering VIR and has increased its forecast on March 03, 2022 with a “Neutral” recommendation from previously “an Underperform” rating. Robert W. Baird revised its rating on December 21, 2021. It rated VIR as “an Underperform” which previously was an “a Neutral”.

Price Performance Review of VIR

On Monday, Vir Biotechnology Inc. [NASDAQ:VIR] saw its stock jump 6.16% to $27.24. On the same session, the stock had its day’s lowest price of $25.62, but rose to a high of $27.43. Over the last five days, the stock has gained 23.93%. Vir Biotechnology Inc. shares have fallen nearly -34.94% since the year began. Nevertheless, the stocks have fallen -12.86% over the past one year. While a 52-week high of $58.00 was reached on 01/03/22, a 52-week low of $18.05 was recorded on 09/23/22. SMA at 50 days reached $21.40, while 200 days put it at $24.91. A total of 1.96 million shares were traded, compared to the trading of 0.71 million shares in the previous session.

Levels Of Support And Resistance For VIR Stock

The 24-hour chart illustrates a support level at 26.10, which if violated will result in even more drops to 24.95. On the upside, there is a resistance level at 27.91. A further resistance level may holdings at 28.57. The Relative Strength Index (RSI) on the 14-day chart is 72.99, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.46, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 2.61%. Stochastics %K at 75.75% indicates the stock is a holding.

How much short interest is there in Vir Biotechnology Inc.?

A steep rise in short interest was recorded in Vir Biotechnology Inc. stocks on Jul 14, 2022, dropping by -0.38 million shares to a total of 7.08 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 7.46 million shares. There was a decline of -5.37%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 8.59% of the overall stock float, the days-to-cover ratio (short ratio) fell to 6.29.

Vir Biotechnology Inc. [VIR] – Who Are The Largest Shareholders?

In filings from BlackRock Fund Advisors, it is revealed that the company now owns 11,538,941 shares, or roughly 8.70% of the outstanding VIR shares. In other words, the investor’s shares have risen by 6,922,924 from its previous 13-F filing of 4616017.0. Additionally, The Vanguard Group, Inc. increased 6.38% of its stake after which the total value it holdings stand at $155,723,018. Over the last quarter, SSgA Funds Management, Inc. purchased 1,325,374 shares of Vir Biotechnology Inc., while Baillie Gifford & Co. bought 47,805 shares. At present, AllianceBernstein LP is holding 2,800,537 shares valued at $53.99 million. Capital Research & Management Co owned 2,660,682 shares of the company at the time of its most recent 13F filing, worth $51.3 million.

According to FactSet, Vir Biotechnology Inc.’s share price will average $38.25 in the next year, based on opinions of analysts polled by the firm. This is up nearly 48.09 percent from its previous closing price of $25.66. Analysts expect Vir Biotechnology Inc. stock to reach the higher price of $67.00, while the lowest price estimate is $18.00. However, 9 analysts have rated VIR stock as an Overweight in their predictions for 2022.

LEAVE A REPLY

Please enter your comment!
Please enter your name here